Eupraxia Pharmaceuticals Future Growth
Future criteria checks 0/6
Eupraxia Pharmaceuticals is forecast to grow revenue at 64.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 34.0% |
| Revenue growth rate | 64.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | N/A | -33 | 15 | 2 |
| 12/31/2025 | N/A | N/A | -28 | -26 | 3 |
| 12/31/2024 | N/A | N/A | -5 | -29 | 3 |
| 9/30/2024 | N/A | -28 | -30 | -30 | N/A |
| 6/30/2024 | N/A | -27 | -26 | -26 | N/A |
| 3/31/2024 | N/A | -30 | -22 | -22 | N/A |
| 12/31/2023 | N/A | -28 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -26 | -19 | -19 | N/A |
| 6/30/2023 | N/A | -24 | -18 | -17 | N/A |
| 3/31/2023 | N/A | -20 | -16 | -16 | N/A |
| 12/31/2022 | N/A | -18 | -15 | -14 | N/A |
| 9/30/2022 | N/A | -14 | -13 | -12 | N/A |
| 6/30/2022 | N/A | -14 | -11 | -11 | N/A |
| 3/31/2022 | N/A | -14 | -12 | -11 | N/A |
| 12/31/2021 | N/A | -19 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -9 | -9 | N/A |
| 6/30/2021 | N/A | -12 | -7 | -7 | N/A |
| 3/31/2021 | N/A | -9 | -4 | -4 | N/A |
| 12/31/2020 | N/A | -3 | 0 | 0 | N/A |
| 9/30/2020 | N/A | -3 | -1 | -1 | N/A |
| 12/31/2019 | N/A | -6 | -4 | -4 | N/A |
| 12/31/2018 | N/A | -10 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EPRX's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if EPRX's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if EPRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EPRX is forecast to have no revenue next year.
High Growth Revenue: EPRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EPRX's Return on Equity is forecast to be high in 3 years time